Is Tislelizumab a chemotherapy drug?

Tislelizumab (Tislelizumab) is not a chemotherapy drug, but an immunotherapy drug, specifically an anti-programmed death receptor-1 (PD-1) monoclonal antibody. It plays an anti-cancer effect by blocking the binding of the PD-1 receptor and its ligand PD-L1 by restoring and enhancing the patient's own immune system's ability to recognize and attack tumor cells. This mechanism makes tislelizumab an important breakthrough in the field of tumor immunotherapy in recent years.

Different from traditional chemotherapy drugs, chemotherapy mainly works by directly killing rapidly dividing tumor cells and to a certain extent normal cells, so it is often accompanied by obvious side effects, such as bone marrow suppression, nausea and vomiting, etc. Tislelizumab, as an immune checkpoint inhibitor, has a more targeted mechanism of action. Its side effects are generally immune-related adverse reactions, such as rash, immune pneumonitis or hepatitis, but it is generally well tolerated.

Clinically, tislelizumab has been approved for the treatment of a variety of cancers, including non-small cell lung cancer, hepatocellular carcinoma, esophageal cancer, urothelial cancer, etc., and is often used in advanced or relapsed and refractory patients, especially when traditional chemotherapy has limited effect or is intolerable. It can be used alone or in combination with chemotherapy to enhance efficacy.

In summary, tislelizumab belongs to the category of immunotherapy, not chemotherapy drugs. It modulates the immune system to attack cancer cells, providing a different treatment strategy from chemotherapy and bringing new hope and options to many cancer patients. During use, patients should closely monitor possible immune-related side effects and carry out standardized treatment under the guidance of a doctor.

Reference materials:https://www.drugs.com